Geneoscopy

April is National Cancer Prevention and Early Detection Month, highlighting the critical role of early detection in the battle against cancer. We honor those currently facing cancer and celebrate the remarkable advancements in research and treatment. Routine screenings, such as colorectal cancer tests, play a vital role in improving health outcomes. Dr. Erica Barnell from Geneoscopy discusses innovative technologies like ColoSense®, a noninvasive RNA-based test developed to make screening more accessible. Read Dr. Barnell's Q&A: https://bit.ly/4c5dMLf Learn about Cancer Prevention and Early Detection Month from Prevent Cancer Foundation: https://bit.ly/3DQhrAh Let's unite to raise awareness, promote healthy lifestyle choices, and encourage regular screenings. Early detection equals better outcomes! ️ #CancerPreventionMonth #EarlyDetection #ColorectalCancerAwareness

We are thrilled to announce that Amit Bhalla has joined Geneoscopy as our new Chief Financial Officer (CFO)! With 25 years of experience in healthcare finance and strategy, Amit will play a pivotal role in advancing our mission to transform gastrointestinal health through innovative diagnostics. Please join us in welcoming Amit to the team! Read the full announcement: https://bit.ly/4hT6Ouh #Geneoscopy #HealthcareInnovation #ColoSense #GastrointestinalHealth #Leadership #CFO #Investment #Diagnostics #HealthcareFinance

March may be ending, but our commitment to raise awareness in the fight against colorectal cancer continues year-round. Make informed decisions about your health. Know your screening options, talk to your healthcare provider, and remember: Screening saves lives. CRC is preventable, treatable, and beatable. #ColorectalCancer #TalkToYourProvider #EndCRC #GetScreened #YearRoundAwareness

We're #hiring a new Director of Revenue Cycle Management in United States. Apply today or share this post with your network.

We're #hiring a new Customer Service Supervisor in United States. Apply today or share this post with your network.

#STLTechWeek is hosting "Breakthrough: A Health Innovation Symposium" on April 3rd at T-REX in Downtown with a free full-day lineup of St. Louis experts talking #biotech and #healthtech - https://lnkd.in/g4ZRQXA5 At Breakthrough, we will hear from the Opening Panel discussion moderated by Scott Huston, Director of Healthcare Business Development at GlobalSTL and BioSTL, along with Erica Barnell, Co-Founder and Chief Medical / Science Officer at Geneoscopy, and Blake Marggraff, CEO of TCARE, Inc. 🎤 "Scaling Science: The Next Stage for St. Louis' HealthTech & Biotech Innovators" As St. Louis continues to emerge as a national leader in HealthTech and Biotech innovation, a new wave of startups is moving beyond early-stage success and into high-growth expansion. This panel will feature founders and executives from the region’s fastest-growing health and life sciences companies who have recently secured growth capital investment (some Series B & C), positioning them for rapid scaling, commercialization, and broader market impact. Panelists will discuss the evolving investment landscape, the strategic milestones that attract later-stage capital, and how they are leveraging funding to expand operations, accelerate clinical development, navigate regulatory pathways, and enter new markets. With growing support from venture capital, corporate partnerships, and a maturing ecosystem, St. Louis’ HealthTech and Biotech scaleups are proving that breakthrough science can translate into high-growth businesses that drive economic and healthcare transformation. 🎫 Register for Breakthrough: https://lnkd.in/g4ZRQXA5

In honor of Colorectal Cancer Awareness Month, we had an insightful discussion with Dr. Erica Barnell about ColoSense®, Geneoscopy's innovative RNA-based colorectal cancer screening test. Did you know? Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., and its incidence is on the rise among younger adults. With early detection, the five-year survival rate can reach 90%! Dr. Barnell emphasizes the need for increased awareness and education and improved access to screening options. ColoSense offers a noninvasive testing option for patients 45+ at average risk that can be completed from the comfort of home. Prioritize your health and help spread the word about the importance of colorectal cancer screening! Read the full interview below. #ColorectalCancerAwareness #Geneoscopy #ColoSense #HealthEquity #EarlyDetection #CancerScreening #HealthcareInnovation

Did you know that more than 1 in 3 individuals in the US are not up to date on colorectal cancer screening? 🚨 Early diagnosis of CRC can significantly improve treatment options and survival rates. Don't delay. Talk with your healthcare provider about getting screened today! Your health is a priority! 💙 #ColorectalCancer #GetScreened #EarlyDetection #HealthAwareness #CancerPrevention

Colorectal cancer (CRC) screening is evolving, and experts like Uri Ladabaum, MD, MS, a member of the Stanford Cancer Institute and professor of medicine (gastroenterology & hepatology), emphasize the necessity for accessible and effective solutions Geneoscopy shares this vision. ColoSense harnesses the power of RNA biomarkers for the qualitative detection of colorectal cancer and advanced adenomas and is indicated for adults 45+ at average risk. Learn more about Dr. Ladabaum’s insights in Stanford Medicine: https://stan.md/4c0jNJf Learn more about ColoSense: https://bit.ly/40sqdNj #ColorectalCancer #Screening #EarlyDetection #AdvancedAdenomas #ColoSense #CancerPrevention